Xyzal Allergy 24hr patents expiration

XYZAL ALLERGY 24HR's oppositions filed in EPO
XYZAL ALLERGY 24HR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8633194 CHATTEM SANOFI Pharmaceutical composition of piperazine derivatives
Oct, 2027

(4 years from now)

Xyzal Allergy 24Hr is owned by Chattem Sanofi.

Xyzal Allergy 24Hr contains Levocetirizine Dihydrochloride.

Xyzal Allergy 24Hr has a total of 1 drug patent out of which 0 drug patents have expired.

Xyzal Allergy 24Hr was authorised for market use on 31 January, 2017.

Xyzal Allergy 24Hr is available in solution;oral dosage forms.

The generics of Xyzal Allergy 24Hr are possible to be released after 16 October, 2027.

Drugs and Companies using LEVOCETIRIZINE DIHYDROCHLORIDE ingredient

Market Authorisation Date: 31 January, 2017

Treatment: NA


How can I launch a generic of XYZAL ALLERGY 24HR before it's drug patent expiration?
More Information on Dosage

XYZAL ALLERGY 24HR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic